Delcath Systems Inc (DCTH)

1.96
NASDAQ : Health Care
Prev Close 1.96
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.35 / 9.60
Avg Volume 141.60K
Exchange NASDAQ
Shares Outstanding 2.20M
Market Cap 4.35M
EPS -14.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Againsttheodds.eu Recognized for High Quality Consumer Health Content

Delcath Announces First CHEMOSAT® Procedures In Turkey

Delcath Announces First CHEMOSAT® Procedures In Turkey

Growing Adoption of CHEMOSAT Permits Expansion Outside of European Union

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical Development

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

Moffitt Cancer Center Begins Patient Enrollment in FOCUS Trial; Study Results to Support U.S. New Drug Application

Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma

Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma

Agreement Provides Regulatory Pathway for Melphalan/HDS with a Single Phase 3 Trial; Satisfies Substantial Number of Requirements in FDA's September 2013 Complete Response Letter

Review Of Delcath Melphalan/HDS System Published In

Review Of Delcath Melphalan/HDS System Published In "Cardiovascular & Interventional Radiology"

First Review of Current Product and Procedure to be used in the Planned Global Phase 3 Trial